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Background-—Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment
beneﬁts by angiotensin-converting enzyme (ACE)-inhibitor therapy vary between individuals. Our objective was to integrate clinical
and pharmacogenetic determinants in an ultimate combined risk prediction model.
Methods and Results-—Clinical, genetic, and outcomes data were used from 8726 stable CAD patients participating in the
EUROPA/PERGENE trial of perindopril versus placebo. Multivariable analysis of phenotype data resulted in a clinical risk score
(range, 0–21 points). Three single-nucleotide polymorphisms (rs275651 and rs5182 in the angiotensin-II type I-receptor gene and
rs12050217 in the bradykinin type I-receptor gene) were used to construct a pharmacogenetic risk score (PGXscore; range, 0–6
points). Seven hundred eighty-ﬁve patients (9.0%) experienced the primary endpoint of cardiovascular mortality, nonfatal
myocardial infarction or resuscitated cardiac arrest, during 4.2 years of follow-up. Absolute risk reductions ranged from 1.2% to
7.5% in the 73.5% of patients with PGXscore of 0 to 2. As a consequence, estimated annual numbers needed to treat ranged from
as low as 29 (clinical risk score ≥10 and PGXscore of 0) to 521 (clinical risk score ≤6 and PGXscore of 2). Furthermore, our data
suggest that long-term perindopril prescription in patients with a PGXscore of 0 to 2 is cost-effective.
Conclusions-—Both baseline clinical phenotype, as well as genotype determine the efﬁcacy of widely prescribed ACE inhibition in
stable CAD. Integration of clinical and pharmacogenetic determinants in a combined risk prediction model demonstrated a very
wide range of gradients of absolute treatment beneﬁt. ( J Am Heart Assoc. 2016;5:e002688 doi: 10.1161/JAHA.115.002688)
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T he European Trial on Reduction of Cardiac Events withPerindopril in Stable Coronary Artery Disease (EUROPA)
and the Heart Outcomes Prevention Evaluation (HOPE) have
demonstrated the effectiveness of angiotensin-converting
enzyme (ACE) inhibitors perindopril and ramipril, respectively,
by reduction of mortality and morbidity from cardiovascular
events among patients with stable coronary artery disease
(CAD).1,2 Consequently, ACE inhibitors are recommended in
clinical guidelines on secondary prevention in patients with
stable CAD and hence widely used in this population.3–5
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However, patients with stable CAD constitute a heteroge-
neous group in which the absolute risk of cardiovascular
complications varies between individuals.6,7
Several approaches toward identiﬁcation of those patients
that are most likely to beneﬁt from ACE-inhibitor therapy have
previously been reported. A previously published post-hoc
analysis of the EUROPA trial studied baseline clinical risk
factors such as age, sex, smoking, cholesterol, and blood
pressure levels.6 A risk score founded on such baseline
clinical risk factors was able to identify patients at high,
medium, and relatively low absolute risk (>3%, 1–3% and 1%
per annum, respectively) of experiencing cardiovascular
death, nonfatal myocardial infarction (MI), and resuscitated
cardiac arrest.6 In contrast to the absolute treatment beneﬁt,
the relative treatment effect of perindopril, however, was not
modiﬁed by the baseline level of risk.6 Similar conclusions
were drawn after investigation of the relation between
treatment beneﬁt by perindopril and baseline renal function
or the degree of blood pressure reduction.8–10
A novel approach toward selection of those that are likely
to respond (or not) to ACE-inhibitor therapy is to identify
information on genetic variation among patients.11 A recent
publication by our group demonstrated that genetic variation
in the renin-angiotensin-aldosterone system (RAAS) and the
kallikrein-bradykinin (KB) pathway is associated with the
treatment beneﬁt of perindopril.12 Three single-nucleotide
polymorphisms (SNPs), 2 of which in the angiotensin-II type I
(AT1) receptor gene and one in the bradykinin type I (BK1)
receptor gene, were used to construct an integer-based
pharmacogenetic risk score (PGXscore), ranging from 0 to 6
points.12 We were able to identify 2 distinct subgroups within
the overall study population of 8726 patients on the basis of
this PGXscore.12 One subgroup (73.5% of the patients) was
characterized by a more pronounced treatment beneﬁt,
whereas no treatment beneﬁt was apparent in the remaining
26.5% of patients.
This current analysis is an ultimate extension of both the
previously published clinical risk model6 and pharmacogenetic
risk proﬁle.12 Its purpose is 2-fold: (1) to investigate the
relation between identiﬁed genetic determinants of treatment
beneﬁt and different levels of baseline clinical risk and (2) to
integrate clinical and pharmacogenetic determinants in an
ultimate combined risk prediction model.
Methods
Study Population and Design
The PERindopril GENEtic association study (PERGENE) is a
substudy of the EUROPA trial. The designs of both studies
have been reported previously.1,12 In brief, the EUROPA trial
was a randomized, double-blinded, placebo-controlled study
designed to assess the effect of perindopril (8 mg daily) on
the combined primary endpoint of cardiovascular mortality,
nonfatal myocardial infarction (MI), and resuscitated cardiac
arrest in 12 218 patients with stable CAD, but without overt
heart failure or uncontrolled hypertension. Use of perindopril
resulted in a 20% relative risk reduction (adjusted hazard ratio
[HR]: 0.80; 95% CI: 0.71–0.91) in the rate of the primary
endpoint during a mean follow-up of 4.2 years.1
A DNA biobank was established within the EUROPA trial for
the purpose of the PERGENE substudy, which investigates
whether genetic variation is a determinant of the risk of future
adverse cardiovascular outcome and/or treatment beneﬁt by
use of perindopril.11 DNA was successfully isolated in 9454
patients, using an automated isolation process.11 Compre-
hensive coverage of genetic variation in both the RAAS and KB
pathways was ensured by a haplotype-tagging SNP procedure
in 12 candidate genes, as described in detail previously.11,12
Our study was approved by the institutional review board
of every participating center and written informed consent for
genetic association analyses was obtained from all patients.
Clinical Risk Score
Uni- and multivariable Cox proportional hazard regression
analyses were performed to study the relation between the
primary endpoint (cardiovascular mortality, nonfatal MI, and
resuscitated cardiac arrest) and baseline clinical patient
characteristics, such as demographic and clinical variables,
medical history, laboratory tests, and concomitant medica-
tion. Interaction by treatment was investigated for each
clinical characteristic. A ﬁnal multivariable clinical risk model
was constructed using a backward step-wise elimination
procedure in which removal testing was based on the
probability of the likelihood ratio statistic based on the
maximum partial likelihood estimates. In order to develop a
clinical risk scoring system, the log HRs from the ﬁnal
multivariable model were converted to an estimated risk
score.6,13 Clinical risk scores were calculated for each of the
patients of the currently described population (only those trial
participants of whom both baseline clinical characteristics
and [pharmaco]genetic proﬁle were complete). The study
population was divided into tertiles in order to distinguish low,
medium, and high clinical risk proﬁles.
Pharmacogenetic Risk Proﬁle and Replication
The PERGENE substudy assessed 52 SNPs with the use of
Taqman allelic discrimination assays (Applied Biosystems,
Foster City, CA) and Sequenom (San Diego, CA) mass
spectrometric genotyping. Quality control for the accuracy
of genotyping involved testing duplicates from a randomly
selected group of samples (5%) for concordance between
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samples (always >99% replication). Individual SNP call rates
ranged between 95% and 98%. To ensure DNA quality, only
patients who were successfully genotyped for more than 90%
of the selected 52 SNPs were included in the PERGENE
analyses (n=8907).12
Seven SNPs have previously been reported to signiﬁcantly
modify the treatment effect of perindopril in univariate
analyses.12 After multivariate adjustment and correction for
multiple testing, 3 SNPs remained signiﬁcant modiﬁers of the
perindopril treatment effect: rs275651 and rs5182 in the AT1
receptor gene and rs12050217 in the BK1 receptor gene.
These 3 SNPs formed the foundation of a previously published
PGXscore, ranging from 0 to 6 points, which was constructed
by counting the number of alleles that were associated with a
decreased beneﬁt of perindopril treatment.12 The association
between the PGXscore and treatment beneﬁt by perindopril,
as found in PERGENE,12 was replicated in the PROGRESS
study, which investigated the treatment effect of perindopril in
patients with cerebrovascular disease.14
Statistical Analysis
Differences in baseline clinical characteristics between low,
medium, and high clinical risk groups were assessed by chi-
square tests in the case of categorical data or 1-way ANOVA
in the case of continuous data. A multivariate Cox propor-
tional hazards regression model was ﬁtted with the following
covariates: clinical risk score; PGXscore; treatment; and
treatment9PGXscore interaction (full model). The baseline
hazard function, H0(t), was estimated by dividing the cumu-
lative hazard at the end of follow-up through the exponential
function of the mean of the covariates. The cumulative
survival under perindopril treatment versus placebo at the
median follow-up of 4.2 years was calculated for each clinical
risk score within the separate pharmacogenetic risk strata as
follows: S (4.2 years)=0.0339759exp (0.1969clinical risk
score0.2039PGXscore0.7939treatment0.3189inter-
action term). With respect to “treatment,” placebo was
deﬁned as 0 and perindopril treatment as 1. The “interaction
term” was the multiplication of the PGXscore9treatment.
Absolute and relative risks, as well as crude and adjusted HRs,
are presented with 95% CIs. Numbers needed to treat (NNT) in
order to prevent 1 event per annum were calculated as the
inverse of the absolute risk reduction at the mean clinical risk
scores per stratum.
The performance of the model consisting of clinical risk
score only was compared by 2 different methods with the full
model with respect to discrimination. First, the c-index and
areas under the 2 receiver operating characteristic curves
were compared by a nonparametric method, as previously
described by de Long et al.15 Secondly, the difference in
model-based discrimination slopes was evaluated through
integrated discrimination improvement (IDI).16 Calibration of
both the model consisting of clinical risk score only and the
full model was tested with the Hosmer-Lemeshow (H-L)
goodness-of-ﬁt test. All statistical tests were 2-sided with a
type I error level of 0.05, except for the IDI, for which a
conservative signiﬁcance level of 0.01 was maintainted.16
We performed a cross-validation within our own data set by
bootstrap methods, as suggested by Harrell et al.17 We
constructed 300 bootstrap samples (training) from the full
original sample with the same size as the original (test).
Models were built in the training sets. C-indices were then
obtained in these training sets (Ctraining) and compared with
the c-indices of the models when applied to the test set
(Ctest). The optimism in the ﬁt from bootstrap sample i is
deﬁned as Oi=Ci,trainingCi,test. We report the mean O of these
optimism estimates. Analyses were performed with IBM SPSS
statistics (version 23.0; IBM Corp, Armonk, NY) and STATA
software (version 12; StataCorp LP, College Station, TX).
Cost-Effectiveness Analysis
We examined the potential cost-effectiveness of the com-
bined clinical risk score and PGXscore. The time horizon was
restricted to the duration of the EUROPA trial/PERGENE study
(mean follow-up of 4.2 years). Costs were set at 15 euros for
the analysis of the 3 SNPs of the PGXscore, 50 euros for
perindopril (based on the current price of perindopril 8-mg
tablets in The Netherlands), and 3000 euros for a clinical
event (a weighted average of the costs of treating MI and the
costs of cardiac death). The health loss of a clinical event
within the trial duration was set at 0.6 years (a weighted
average of the relative frequency and life-years lost from MI
[0 years] and cardiac death [2 years]).
The following patient management strategies were exam-
ined, against the strategy of no perindopril treatment (as the
comparator):
• Pharmacogenetic testing only in patients with a high clinical
risk score and perindopril treatment only if PGXscore=0 to
2
• Pharmacogenetic testing only in patients with a medium or
high clinical risk score and perindopril treatment only if
PGXscore=0 to 2
• Pharmacogenetic testing in all patients and perindopril
treatment only if PGXscore=0 to 2
• Perindopril treatment in all patients irrespective of PGX
score.
Results
Complete data on baseline clinical patient characteristics and
(pharmaco)genetic proﬁle were obtained for 8726 patients (of
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which 4338 were allocated to perindopril and 4388 to
placebo). Median follow-up was 4.2 years (interquartile range:
4.0–4.5), during which 785 patients (9.0%) experienced the
primary endpoint of cardiovascular mortality, nonfatal MI or
resuscitated cardiac arrest. Treatment with perindopril was
protective in the overall study population; the number of
patients on perindopril treatment that experienced the
primary endpoint was 346 (8.0%) versus 439 (10.0%) on
placebo (adjusted HR: 0.80; 95% CI: 0.68–0.92). Baseline
characteristics of the overall study population and various
subgroups according to the clinical risk level are provided in
Table 1. Interaction between study treatment and clinical
characteristics (including concomitant medication) was not
found.
Signiﬁcant baseline clinical risk predictors and the point-
scoring system, which derived from backward elimination, are
presented in Table 2. The log HRs from the ﬁnal multivariable
model that were converted to the clinical risk score are
provided in Table S1. The clinical risk score could theoretically
range from 0 to 32, yet calculated individual scores within our
study population ranged from 0 to 21 with a mean value of
7.672.83 (Figure 1). The 33rd and 67th percentiles were at
6.00 and 9.00 points, respectively, and used as cutoffs in
order to distinguish low, medium, and high clinical risk levels.
The skewness of the distribution (Figure 1) prevented forma-
tion of 3 groups of similar size. It should be noted that the
high-risk group consists of 23.9% of the overall study
population (Tables 1 and 3). Incidences of all known baseline
cardiovascular risk factors were highest in the higher clinical
risk groups (Table 1), with the exception of previously
diagnosed hypercholesterolemia, which actually was lowest
in the high-risk subgroup. In accord, high-risk patients also
presented with the lowest rate of statin use. These ﬁndings,
however, were counterbalanced by the fact that patients in
the high-risk subgroup did have the highest total cholesterol
levels (Table 1).
The primary endpoint rates in the low, medium, and high
clinical risk groups were 4.6%, 8.8%, and 16.2%, respectively
(P<0.001; Table 1). These differences in event rate can be
explained by the observed differences in baseline clinical risk
factors, but not by confounding attributed to study drug
allocation, given that the latter was similar over the 3 clinical
risk strata (P=0.296; Table 1).
Adjusted HRs for the treatment effect of perindopril were
0.72, 0.70, and 0.91 for the lowest to highest clinical risk
tertiles, respectively. Heterogeneity of treatment effect was
tested and ruled out (P=0.31). Thus, the relative treatment
beneﬁt was not modiﬁed by the baseline clinical risk level.
However, baseline clinical risk level did modify absolute risk
reductions. Use of perindopril in the overall study population
(n=8726) resulted in a 2.23% risk reduction of the primary
endpoint (95% CI: 1.03–3.44; annual NNT: 189; 95% CI: 122–
401). However, absolute risk reductions varied from 1.24% to
2.17% and 3.97% in the lowest, medium, and highest clinical
risk tertiles. As a consequence, NNTs were inversely related
to increasing clinical risk scores (Table 4).
The pharmacogenetic risk scoring system, based on the
previously identiﬁed 3 SNPs, is presented in Table S2. Risk
alleles for lack of treatment beneﬁt were T, C, and G for
Rs275651, Rs5182 and Rs12050217, respectively. The
individual PGXscores range from 0 to 6 points with a mean
value of 1.821.13 (Table 1). Signiﬁcant heterogeneity of
treatment effect across pharmacogenetic proﬁles was
observed. A pronounced treatment beneﬁt was observed in
6410 patients (73.5%), with PGXscore <3 (adjusted HR: 0.67;
95% CI: 0.56–0.79), whereas no beneﬁt was observed in the
remaining subgroup of 2316 patients (26.5%) with PGXscore
≥3 (adjusted HR: 1.26; 95% CI: 0.97–1.67; Table 3 for patient
distribution).
Use of perindopril in patients with PGXscores of 0 and 1
point resulted in absolute risk reductions of 7.50% (95% CI:
3.69–11.73) and 4.30% (95% CI: 2.00–6.53), respectively.
Consequently, annual NNTs were 55 (95% CI: 113–38) for
patients with a PGXscore of 0 and 97 (95% CI: 210–63) for
patients with a PGXscore of 1. The point estimate of the
absolute risk reduction associated with use of perindopril in
the subgroup of PGXscore of 2 was in the same positive
direction, yet nonsigniﬁcant (1.34%; 95% CI: 0.77 to 3.47;
and NNT [per annum]=311; 95% CI: 546 to 122).
In contrast, a nonsigniﬁcant estimated absolute risk
increase of 1.32% was observed in patients with a PGXscore
≥3 using perindopril (95% CI for risk increase: 0.97 to 3.67
and NNT [per annum]=315; 95% CI: 118 to 433).
Combined Baseline Clinical and Pharmacogenetic
Risk Proﬁles
Mean pharmacogenetic risk scores were identical over all 3
clinical risk strata (P=0.435; Table 1), and formal testing did
not trace interaction between clinical and PGXscores. The
Distribution of patients over the various clinical and pharma-
cogenetic risk strata is given in Table 3. Figures 2A through
2D describe the relation between absolute risks of the
primary endpoint, clinical risk proﬁle, and treatment for each
of the separate pharmacogenetic risk strata. Lack of
treatment beneﬁt was observed across the entire spectrum
of clinical risk in patients with a PGXscore ≥3 (Figures 2D
and 3).
Increasing clinical risk scores led to increasingly pro-
nounced risk differences between perindopril and placebo in
all pharmacogenetic strata. Hence, extremes of treatment
effect were found in patients with high clinical risk proﬁles.
For example, use of perindopril in patients with a clinical risk
score of 19 resulted in an estimated absolute risk reduction of
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28.42% (95% CI: 22.46–34.09) in the case of a PGXscore of 0
versus an estimated risk increase of 5.82% (95% CI: 1.78–9.83)
in the case of a PGXscore ≥3 (Figure 3). Concordantly, NNTs
decreased in subgroups with higher clinical risk proﬁles and
lower PGXscores, both of which were associated with more
pronounced treatment effects (Table 4). Estimated NNTs were
as low as 29 (95%CI: 17–113) in patients with a high clinical risk
proﬁle and a PGXscore of 0, whereas those with a low clinical
risk proﬁle and a PGXscore of ≥3 did not experience any beneﬁt
(NNT=529; 95% CI: 105 to 189).
Table 1. Baseline Study Population Characteristics
Total Population
Clinical Risk Level
P Value*Low Medium High
N (%) 8726 3167 (36.3) 3474 (39.8) 2085 (23.9)
Age, y 59.8 (9.3) 57.7 (8.0) 59.4 (9.2) 63.8 (10.0) <0.001
Male sex (%) 85.5 81.5 87.6 88.2 <0.001
Hypertension (%)† 29.0 23.0 28.0 39.0 <0.001
Diabetes mellitus (%) 13.0 4.0 11.0 30.0 <0.001
Hypercholesterolemia (%)‡ 63.0 69.0 60.0 58.0 <0.001
Current smoking (%)§ 15.0 6.0 16.0 25.0 <0.001
Obesity (BMI >30 kg/m2) (%) 21.3 8.2 24.0 36.7 <0.001
Symptomatic CAD (%)k 25.4 9.5 25.9 48.9 <0.001
Family history of CAD (%) 27.0 22.0 29.0 32.0 <0.001
Previous MI (%) 65.0 44.0 73.0 84.0 <0.001
Previous revascularisation (%) 55.0 75.0 49.0 33.0 <0.001
Previous stroke or PAD (%) 8.9 0.8 5.2 27.5 <0.001
Concommitant medication
Platelet inhibitors (%) 92.0 94.0 92.0 89.0 <0.001
Beta-blockers (%) 63.0 62.0 65.0 63.0 0.104
Lipid-lowering agents (%) 55.0 64.0 53.0 46.0 <0.001
Calcium antagonists (%) 32.0 29.0 31.0 37.0 <0.001
Systolic blood pressure, mm Hg 136.9 (15.2) 132.7 (13.9) 137.7 (15.1) 142.1 (15.5) <0.001
Diastolic blood pressure, mm Hg 81.8 (8.1) 80.6 (7.9) 82.4 (8.1) 82.7 (8.3) <0.001
Creatinine clearance, lmol/L¶ 86.5 (25.7) 88.9 (22.2) 87.7 (26.6) 80.9 (28.3) <0.001
Total cholesterol, mmol/L 5.4 (1.0) 5.1 (0.9) 5.5 (1.0) 5.7 (1.1) <0.001
Outcome
Randomization, allocation to perindopril (%) 49.7 51.0 48.9 49.5 0.296
Primary endpoint (%) 9.0 4.6 8.8 16.2 <0.001
Systolic/diastolic blood pressure
reduction by perindopril, mm Hg#
8.6/4.0 7.3/3.9 9.2/4.1 9.6/4.1 <0.001/0.416
Risk score 0 to 6 7 to 9 10 to 21
Mean clinical risk score 7.67 (2.83) 4.84 (1.20) 7.93 (0.80) 11.53 (1.74) N.A.
Mean pharmacogenetic risk score 1.82 (1.13) 1.82 (1.12) 1.82 (1.12) 1.86 (1.11) 0.435
Summary statistics for continuous variables are presented as mean (SD). Categorical data are summarized as percentages. BMI indicates body mass index; CAD, coronary artery disease;
MI, myocardial infarction; N.A., not applicable; PAD, peripheral artery disease.
*For differences between low, medium, and high clinical risk levels.
†
Blood pressure >140/90 mm Hg or receiving antihypertensive treatment.
‡
Previously known total cholesterol >6.5 mmol/L or receiving lipid-lowering treatment.
§
Use of tobacco within the last month.
k
Stable angina pectoris or history of congestive heart failure.
¶
Estimation by Cockroft-Gault equation.
#
Blood pressure reduction was calculated as the mean difference in blood pressure from screening visit 1 to randomization after the 4-week run-in period of the Europa trial in which all
patients were treated with perindopril.
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In separate analyses with only cardiovascular mortality or
nonfatal MI as sole endpoint, we observed directional
concordance, compared to the presented analysis of the
combined primary endpoint, with respect to NNTs over the
various clinical and pharmacogenetic risk strata.
Discrimination and Calibration of the Clinical and
Combined Risk Models
Calibration and discrimination were assessed for 2 models:
(1) the model consisting of clinical risk score only and (2) the
full model consisting of clinical risk score, PGXscore, and
treatment9PGXscore interaction.
Addition of pharmacogenetic information on top of clinical
risk proﬁle resulted in better discrimination. The c-index for
the full model (0.68; 95% CI: 0.66–0.70) was signiﬁcantly
higher than the c-index for the model consisting of the clinical
risk score only (0.66; 95% CI: 0.64–0.68; P=0.0015). The full
model also resulted in a signiﬁcantly better discrimination
when assessed with integrated discrimination improvement
(magnitude of increase in IDI: 0.00472; P=0.0002). Validation
of both models by bootstrap methods showed that the bias in
the estimated discrimination performance (c-index) is likely to
be small, because the mean optimism estimates were only
0.006 and 0.007 for the clinical risk score and the full model,
respectively. Finally, the H-L goodness-of-ﬁt tests were
nonsigniﬁcant (P=0.43 for the model with the clinical risk
Table 2. Clinical Risk Scores of Baseline Risk Parameters
Continuous Clinical Risk Parameters
Clinical
Risk
Score
PointsAge, y
Systolic
Blood
Pressure
Creatinine
Clearance
Total Cholesterol,
mmol/L (mg/dL)
<67 ≤130 >70 ≤3.5 (≤135) 0
67 to 69 >130 to ≤160 >55 to ≤70 >3.5 to ≤5.0
(>135–≤193)
1
70 to 72 >160 >35 to ≤55 >5.0 to ≤6.5
(>193–≤251)
2
73 to 76 ≤35 >6.5 to ≤8.0
(>251–≤309)
3
77 to 79 >8.0 (>309) 4
80 to 82 5
83 to 85 6
>85 7
Dichotomous Clinical Risk Parameters Clinical Risk Score Points
Previous stroke or PAD 3
Male sex 2
Obesity (BMI >30 kg/m2) 2
Current smoking 2
Symptomatic CAD 2
Diabetes mellitus 2
Previous MI 2
Family history of CAD 1
Previous revascularisation 1
The range of clinical risk scores=0 to 32 and points for each of applicable variables need
to be added to each other. BMI indicates body mass index; CAD, coronary artery disease;
MI, myocardial infarction; PAD, peripheral artery disease.
Figure 1. Clinical risk score distribution. The mean value of the
clininal risk score (N=8726) was of 7.672.83.
Table 3. Distribution of Patients Over Clinical and
Pharmacogenetic Risk Strata
Clinical risk level Low Medium High
Clinical risk score 0 to 6 7 to 9 10 to 21
Pharmacogenetic risk score N (%)
0 362 (4.1) 390 (4.5) 232 (2.7)
1 945 (10.8) 1037 (11.9) 618 (7.1)
2 1027 (11.8) 1144 (13.1) 655 (7.5)
≥3 833 (9.5) 903 (10.3) 580 (6.6)
Treatment beneﬁt of perindopril was only demonstrated within the group of patients with
pharmacogenetic risk scores <3 (N=6410, 73.5% of the total study population). The
linear-by-linear association P value for the entire table is 0.43.
Table 4. Numbers Needed to Treat (Per Annum)
Clinical risk level Low Medium High
Clinical risk score 0 to 6 7 to 9 10 to 21
NNT per clinical risk stratum 382 218 119
NNT per pharmacogenetic risk stratum
0 93 54 29
1 164 92 50
2 521 298 164
≥3* 529 302 164
*Stratum with nonsigniﬁcant risk increase attributed to use of perindopril. NNT indicates
numbers needed to treat.
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score only and P=0.94 for the full model), indicating adequate
calibration for both models (Figure 4).
Cost-Effectiveness of Tailored Perindopril
Treatment on the Basis of Pharmacogenetic
Testing
The results of the cost-effectiveness analysis, against the
strategy of no treatment with perindopril as comparator, are
displayed in Table 5.
The highest number of gained life-years is observed in
strategies 3 and 4. Strategy 3 implies that all patients are
genetically tested and only those with a PGXscore of 0 to 2
are treated with perindopril. Strategy 4 implies that none of
the patients are genetically tested and all are treated with
perindopril. Strategy 4, however, is dominated by strategy 3.
The lower incremental cost-effectiveness ratio (ICER) of
strategy 3 indicates that tailored perindopril therapy on the
basis of the PGXscore will ultimately reduce costs, with a
similar effectiveness in terms of gained life-years.
Strategy 1 results in the least life-years gained, but also
in the least costs and the lowest ICER and therefore may be
an option when strictly reasoning from the cost perspective
alone.
Figure 2. Absolute risks of the primary endpoint across different clinical (X-axis) and pharmocogenetic
risk strata (Panels A through D). P values were derived from multivariate Cox proportional hazards
regression models ﬁtted with the following covariates: clinical risk score; PGXscore; treatment; and
treatment9PGXscore interaction. PGXscore indicates pharmacogenetic risk score.
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Discussion
The present study highlights that clinical as well as pharma-
cogenetic determinants independently modify absolute treat-
ment beneﬁt by ACE inhibitor perindopril in a population of
patients with stable CAD. Moreover, both clinical and
pharmacogenetic proﬁles could be expressed in risk scores
that are fairly simple to use for clinical decision making. We
propose the use of a PGXscore on top of known clinical risk
factors for better risk stratiﬁcation and more concrete
estimation of absolute treatment beneﬁts of ACE-inhibitor
therapy in daily clinical practice. Increasing clinical risk scores
and decreasing PGXscores were consistently and positively
related to the absolute treatment beneﬁt by ACE-inhibitor
perindopril. Impressive risk gradients and, as a consequence,
important differences in NNT were found across various
subgroups. The annual NNT in the overall study population
was 189, whereas estimates as low as 106 for the entire
clinical high-risk subgroup and even 29, in case of a combined
high clinical risk proﬁle and a PGXscore of 0, were observed.
On the other hand, the entire subgroup of patients with a
PGXscore ≥3 (26.5% of the overall study cohort) was
characterized by a lack of treatment beneﬁt, which was
consistent across all 3 clinical risk levels.
The clinical risk score in our study was based upon easily
obtainable traditional risk factors that have repeatedly proven
to be valuable predictors.18–20 The full model predicted the
highest absolute risk reductions in patients with higher
clinical risk proﬁles. In this regard, it remains important to
emphasize that formally no heterogeneity of relative treat-
ment effect was found across the various clinical risk levels.
Furthermore, the mean clinical risk score in the high-risk level
was 11.53. Scores of, for example, 19 can therefore be
regarded as extremely high. Such extreme risk scores were
under-represented in our randomized, clinical trial data, but
nevertheless such patients do present themselves in clinical
practice. It is plausible that in such extremely high-risk
individuals, the risk is largely determined by the aforemen-
tioned risk factors, and that an ACE inhibitor alone will have
relatively less effect on survival. In other words, the magni-
tude of both controllable and uncontrollable clinical risk
factors in such a patient could have a relatively more
profound effect on the risk of reaching the primary endpoint
than the potential relative treatment beneﬁt by an ACE
inhibitor alone. Obviously, the absolute risk beneﬁt will
remain high in such patients, and treatment with an ACE-
inhibitor should therefore be warranted. This ﬁnding, how-
ever, once again emphasizes the necessity of proper
management of all controllable risk factors in patients with
stable CAD.
Figure 3. Absolute risk reduction (Y-axis on a 0 to 1 scale) by
perindopril across different levels of clinical (X-axis) and pharma-
cogenetic risk. PGXscore indicates pharmacogenetic risk score.
Figure 4. Observed versus estimated risks according to the clinical and combined (full) risk prediction
models. P values were derived from Hosmer-Lemeshow goodness-of-ﬁt test.
DOI: 10.1161/JAHA.115.002688 Journal of the American Heart Association 8
PERGENE Risk Model Oemrawsingh et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at NHLI - Royal Brompton on April 4, 2016http://jaha.ahajournals.org/Downloaded from 
With this in mind, it is remarkable that a history of coronary
revascularization was associated with a modestly reduced risk
for the primary endpoint (1 point) in the presented risk
model. This particular observation should be interpreted with
some reservation, given that several speciﬁcally designed
trials, such as RITA-2,21 COURAGE,22 and BARI 2D,23 failed to
demonstrate survival beneﬁt of coronary revascularization
over optimal medical therapy.
The pharmacogenetic risk score in our study was based
upon 3 SNPs that have previously emerged after comprehen-
sive coverage of the RAAS and KB systems and subsequent
correction for multiple testing.12 Furthermore, the pharmaco-
gentic risk score has previously been replicated in participants
of the PROGRESS-trial.12 Clinical risk factors,6 renal function,8
degree of blood pressure reduction,9 and a number of
biomarkers24,25 have been explored within the EUROPA trial,
yet only pharmacogenetic information has permitted to
distinguish responders to perindopril from nonresponders
(26.5% of all patients). Furthermore, the PGXscore accentuated
striking differences in absolute treatment beneﬁts of ACE-
inhibitor therapy within each of the separate clinical risk strata.
The data that are presented here are unique. Although it is
widely recognized that both phenotype as well as genotype
play a fundamental role in health and disease outcome, very
few reports exist that actually combine both for prognostica-
tion. To our best knowledge, this is the ﬁrst and only article
that combines clinical and genetic information in patients with
CAD. Pharmacogenetic information is successfully translated
into a potential clinical utility to study the gradients of
treatment effect by an ACE inhibitor. The sample size is large
and various additional qualities of a well-designed placebo-
controlled, double-blinded RCT, such as high-quality phe-
notypical data and independent event adjudication, are
apparent. Previous studies that have investigated the relation
between genetic variation and treatment beneﬁt by ACE-
inhibitor therapy usually were characterized by small sample
sizes and nonrandomized designs without placebo controls.26
Only 2 studies with large sample sizes have been reported.
Harrap et al. studied macrovascular events, dementia, and
cognitive decline in 5688 patients with a history of cere-
brovascular disease in the PROGRESS study and found no
interaction between genetic variation and treatment beneﬁt
by perindopril.27
Negative ﬁndings were also published by the GenHAT
investigators, who studied cardiovascular mortality and non-
fatal MI in 7528 patients on a lisinopril-based regimen in the
setting of an active-controlled RCT.28 These 2 studies obviously
differ from our present study in the type of study population,
endpoints, and study drug. The most remarkable difference
with our study, however, is the fact that both studies solely
focussed on a single ACE insertion/deletion polymorphism,
thus not taking account of the full complexity of the RAAS and
KB systems. Furthermore, our PGXscore was replicated in the
PROGRESS study, in which a similar direction and magnitude of
pharmacogenetic interaction was observed.12
Our ﬁndings also have some limitations. This study
describes differences in treatment beneﬁt across a range of
clinical and genetic subgroups. The constituents of the clinical
scoring system are all well-established cardiovascular risk
factors, and the PGXscore has been replicated. Still, it is
important to realize that, in general, any post-hoc analysis
based on subgroups should primarily be regarded as hypoth-
esis generating. Conﬁrmation of our ﬁndings in other large
data sets would invigorate the presented conclusions and
derived clinical implications. The EUROPA trial was powered
for detection of treatment beneﬁt for the entire study
population irrespective of clinical or pharmacogenetic risk
categories. Thus, lack of power cannot be excluded as an
explanation for the observed nonsigniﬁcant treatment beneﬁt
in the higher PGX scores. On the other hand, it must be noted
that the absolute numbers of study participants in PGXscores
≥2 are higher than those below (Table 3).
Patients enrolled in the EUROPA trial primarily consisted of
Caucasian males without overt heart failure, who were
Table 5. Costs, Gained Life-Years, and Incremental Cost-Effectiveness Ratio of Various Treatment Strategies, Against the Strategy
of No Treatment With Perindopril as Comparator
Strategy
No. of Patients Treated
With Perindopril, N (%)
Incremental Costs
(Weighted)
Life-Years Gained
(Weighted) ICER
1. Pharmacogenetic testing only in patients with a high clinical risk score (≥10)
and perindopril treatment only if PGXscore=0 to 2
1505/8726 (17.2) 30.38 0.0017 18 139
2. Pharmacogenetic testing only in patients with a medium or high clinical risk
score (≥7) and perindopril treatment only if PGXscore=0 to 2
4076/8726 (46.7) 90 0.0032 27 987
3. Pharmacogenetic testing in all patients and perindopril treatment only if
GXscore=0 to 2
6410/8726 (73.5) 147 0.0040 36 743
4. Perindopril treatment in all patients irrespective of PGXscore 8726 (100) 232 0.0035 67 230
The time horizon was restricted to the duration of the EUROPA trial/PERGENE study (mean follow-up of 4.2 years). Costs are in euros. ICER indicates incremental cost-effectiveness ratio;
PGXscore, pharmacogenetic risk score.
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randomized to placebo or perindopril 8 mg daily. The
generalizability of the presented results toward other patient
groups, for example, those with a higher proportion of women,
heart failure, patients of other ethnicities, or those using other
ACE inhibitors or lower dosages of perindopril, may therefore
be limited. Testing of these particular genetic variants in a
large, randomized heart failure trial would be required before
suggesting that the same phenomenon exists in that very
different patient group.
Our combined primary endpoint consisted of cardiovascu-
lar mortality, nonfatal MI, and resuscitated cardiac arrest.
Resuscitated cardiac arrest, however, only occurred in very
few instances. Therefore, our results with respect to clinical
and pharmacogenetic determinants of treatment beneﬁt are
primarily associated with incidence of cardiovascular mortality
and nonfatal MI.
In order to facilitate clinical utility and ease of use, we
speciﬁcally chose to develop an integer-based risk score.
Disadvantages of integer-based risk scores in general include
the fact that not all variables have exactly the same
contribution to the model. Furthermore, certain combinations
of risk factors may act synergistically to increase risk in a
manner that is more than additive. Such synergy may be
underestimated in a purely additive, integer-based risk
score.29
Replication of the 3 SNPs that formed the PGXscore in the
PROGRESS trial14 demonstrated concordant associations
between the risk score and treatment beneﬁt by perindopril.12
The individual interaction terms of the 3 SNPs, however, did
not reach statistical signiﬁcance in that particular trial
because of limited statistical power (replication could take
place in 1051 patients only). Unfortunately, larger replication
cohorts are not available.
Although the clinical risk model consists of established
cardiovascular risk factors, formally the combined clinical and
pharmacogenetic risk score has not been independently
validated on a separate data set.
Finally, our risk model does not contain data on circulating
serum biomarkers other than total cholesterol and creatinine
levels. A prespeciﬁed substudy of the EUROPA trial, called
PERTINENT, actually did study bradykinin and angiotensin II,
but also markers of endothelial function (nitric oxide
synthase) and inﬂammation (C-reactive protein, tumour
necrosis factor alpha, and von Willebrand factor). Use of
perindopril was reﬂected in various circulating biomarker
levels, which were interpreted as a biochemical indication of
normalization of the angiotensin II/bradykinin balance, reduc-
tion of inﬂammation, and prevention of endothelial apopto-
sis.24,25 Unfortunately, the cohort in which these biomarkers
were assessed was too small in order to properly study the
interaction between the various serum biomarkers and
treatment effect by perindopril on clinical endpoints.
In conclusion, our results show that a combination of
phenotypical and genetic information can be used to demon-
strate a range of gradients of absolute treatment beneﬁt by
ACE-inhibitor therapy in an otherwise seemingly homoge-
neous population of patients with stable CAD. Clinical and
pharmacogenetic proﬁling in individual patients may both
clarify their distinct level of absolute risk of adverse events
and furthermore also the degree of risk reduction by an ACE-
inhibitor regimen. Refraining from ACE-inhibitor therapy in
those patients that are expected to lack any treatment beneﬁt
may avoid unnecessary side effects, reduce health care costs,
and increase overall efﬁcacy of the drug. Future RCTs could
advance the ﬁeld of individualized medicine by incorporation
of a similar combined clinical and pharmacogenetic approach
in their study design.
Acknowledgments
Oemrawsingh, Brugts, and Prof Boersma were instrumental in the
conception and drafting of the manuscript. All other co-authors have
reviewed, critically revised the intellectual content of, and ﬁnally
approved submission of the manuscript. Oemrawsingh, Brugts, and
Boersma had full access to all study data and take responsibility for
the integrity of the data and the accuracy of the analysis.
Sources of Funding
The PERGENE study is funded by a Dutch noncommercial
charity: the Netherlands Heart Foundation (Grant No.:
NHS2005B219). Oemrawsingh is supported by the Nether-
lands Heart Foundation (Grant No.: NHS2007B012). Prof Kim
Fox is a National Institute for Health Research (NIHR) senior
investigator, supported by the NIHR Cardiovascular Biomed-
ical Medical Research Unit at the Royal Brompton Hospital.
Disclosures
There is no commercial association that might pose a conﬂict
of interest in connection with this manuscript. The sponsor of
the EUROPA trial, Servier, had no role in the design, conduct,
analysis, or interpretation of this substudy, nor in the
preparation, review, or approval of the manuscript.
References
1. Fox KM. Efﬁcacy of perindopril in reduction of cardiovascular events among
patients with stable coronary artery disease: randomised, double-blind,
placebo-controlled, multicentre trial (the EUROPA study). Lancet.
2003;362:782–788.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in
high-risk patients. The Heart Outcomes Prevention Evaluation Study Investi-
gators. N Engl J Med. 2000;342:145–153.
3. Fox K, Garcia MAA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De
Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U,
Simoons M, Thygesen K, Priori SG, Blanc J-J, Budaj A, Camm J, Dean V, Deckers
DOI: 10.1161/JAHA.115.002688 Journal of the American Heart Association 10
PERGENE Risk Model Oemrawsingh et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at NHLI - Royal Brompton on April 4, 2016http://jaha.ahajournals.org/Downloaded from 
J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo
J, Zamorano JL. Guidelines on the management of stable angina pectoris:
executive summary: the task force on the management of stable angina
pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–
1381.
4. Fraker TD, Fihn SD; Writing on behalf of the 2002 Chronic Stable Angina
Writing Committee, 2002 WRITING COMMITTEE MEMBERS, Gibbons RJ,
Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB, Fihn
SD, Fraker TD, Gardin JM, O’Rourke RA, Pasternak RC, Williams SV, Smith SC,
Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM,
Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page
RL, Riegel B, Tarkington LG, Yancy CW. 2007 chronic angina focused update of
the ACC/AHA 2002 guidelines for the management of patients with chronic
stable angina: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines Writing Group to develop the
focused update of the 2002 guidelines for the management of patients with
chronic stable angina. Circulation. 2007;116:2762–2772.
5. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R,
Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM,
Orth-Gomer K, Perk J, Py€or€al€a K, Rodicio JL, Sans S, Sansoy V, Sechtem U,
Silber S, Thomsen T, Wood D, Albus C, Bages N, Burell G, Conroy R, Christian
Deter H, Hermann-Lingen C, Humphries S, Fitzgerald A, Oldenburg B,
Schneiderman N, Uutela A, Williams R, Yarnell J, Priori SG, Angeles Alonso
Garcia M, Blanc J-J, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E,
Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth O,
Trappe H-J, Budaj A, Agardh C-D, Bassand J-P, Deckers J, Godycki-Cwirko M,
Heagerty A, Heine R, Home P, Priori S, Puska P, Rayner M, Rosengren A,
Sammut M, Shepherd J, Siegrist J, Simoons M, Tendera M, Zanchetti A.
European guidelines on cardiovascular disease prevention in clinical practice.
Eur Heart J. 2003;24:1601–1610.
6. Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R, Remme
WJ, Fox K, Simoons ML; on behalf of the EUROPA Investigators. Treatment
beneﬁt by perindopril in patients with stable coronary artery disease at
different levels of risk. Eur Heart J. 2006;27:796–801.
7. Pitt B. ACE inhibitors for patients with vascular disease without left
ventricular dysfunction—may they rest in PEACE? N Engl J Med. 2004;351:
2115–2117.
8. Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ, Ferrari
R, Fox K, Simoons ML. The cardioprotective effects of the angiotensin-
converting enzyme inhibitor perindopril in patients with stable coronary artery
disease are not modiﬁed by mild to moderate renal insufﬁciency: insights from
the EUROPA trial. J Am Coll Cardiol. 2007;50:2148–2155.
9. Remme WJ, Deckers JW, Fox KM, Ferrari R, Bertrand M, Simoons ML.
Secondary prevention of coronary disease with ACE inhibition–does blood
pressure reduction with perindopril explain the beneﬁts in EUROPA? Cardio-
vasc Drugs Ther. 2009;23:161–170.
10. Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K,
MacMahon S, Chalmers J, Simoons ML. The consistency of the treatment
effect of an ACE-inhibitor based treatment regimen in patients with vascular
disease or high risk of vascular disease: a combined analysis of individual data
of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009;30:1385–
1394.
11. Brugts JJ, de Maat MPM, Boersma E, Witteman JCM, van Duijn C, Uitterlinden
AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AHJ, Simoons ML. The
rationale and design of the PERindopril GENEtic association study (PERGENE):
a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor
therapy in patients with stable coronary artery disease. Cardiovasc Drugs
Ther. 2009;23:171–181.
12. Brugts JJ, Isaacs A, Boersma E, van Duijn CM, Uitterlinden AG, Remme W,
Bertrand M, Ninomiya T, Ceconi C, Chalmers J, MacMahon S, Fox K, Ferrari R,
Witteman JCM, Danser AHJ, Simoons ML, de Maat MPM. Genetic determinants
of treatment beneﬁt of the angiotensin-converting enzyme-inhibitor perindopril
in patients with stable coronary artery disease. Eur Heart J. 2010;31:
1854–1864.
13. Sullivan LM, Massaro JM, D’Agostino RB. Presentation of multivariate data for
clinical use: the Framingham Study risk score functions. Stat Med.
2004;23:1631–1660.
14. Randomised trial of a perindopril-based blood-pressure-lowering regimen
among 6,105 individuals with previous stroke or transient ischaemic attack.
Lancet. 2001;358:1033–1041.
15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two
or more correlated receiver operating characteristic curves: a nonparametric
approach. Biometrics. 1988;44:837–845.
16. Pencina MJ, D’Agostino RB, D’Agostino RB, Vasan RS. Evaluating the added
predictive ability of a new marker: from area under the ROC curve to
reclassiﬁcation and beyond. Stat Med. 2008;27:157–172; discussion 207–12.
17. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and measuring and
reducing errors. Stat Med. 1996;15:361–387.
18. Conroy RM, Py€or€al€a K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De
Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen
T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM.
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the
SCORE project. Eur Heart J. 2003;24:987–1003.
19. Clayton TC, Lubsen J, Pocock SJ, Voko Z, Kirwan B-A, Fox KAA, Poole-Wilson
PA; on behalf of the ACTION investigators. Risk score for predicting death,
myocardial infarction, and stroke in patients with stable angina, based on a
large randomised trial cohort of patients. BMJ. 2005;331:869.
20. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang W-C, Lee KL,
Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf
RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute
coronary syndromes without persistent ST-segment elevation: results from an
international trial of 9461 patients. Circulation. 2000;101:2557–2567.
21. Coronary angioplasty versus medical therapy for angina: the second
Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial
participants. Lancet. 1997;350:461–468.
22. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson
M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz
S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS,
Mancini GBJ, Weintraub WS. Optimal medical therapy with or without PCI for
stable coronary disease. N Engl J Med. 2007;356:1503–1516.
23. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard
TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TLZ, Molitch ME,
Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes
and coronary artery disease. N Engl J Med. 2009;360:2503–2515.
24. Ceconi C, Fox K, Remme W, Simoons M, Bertrand M, Parrinello G, Kluft C,
Blann A, Cokkinos D, Ferrari R. ACE inhibition with perindopril and endothelial
function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc
Res. 2007;73:237–246.
25. Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary
artery disease. Drugs. 2009;69:265–277.
26. Danser AHJ, Batenburg WW, van den Meiracker AH, Danilov SM. ACE
phenotyping as a ﬁrst step toward personalized medicine for ACE inhibitors.
Why does ACE genotyping not predict the therapeutic efﬁcacy of ACE
inhibition? Pharmacol Ther. 2007;113:607–618.
27. Harrap SB, The ACE. Gene I/D polymorphism is not associated with the blood
pressure and cardiovascular beneﬁts of ACE inhibition. Hypertension.
2003;42:297–303.
28. Arnett DK. Pharmacogenetic association of the angiotensin-converting enzyme
insertion/deletion polymorphism on blood pressure and cardiovascular risk in
relation to antihypertensive treatment: the Genetics of Hypertension-
Associated Treatment (GenHAT) study. Circulation. 2005;111:3374–3383.
29. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for
the assessment of cardiovascular risk: a review for clinicians. J Am Coll
Cardiol. 2009;54:1209–1227.
DOI: 10.1161/JAHA.115.002688 Journal of the American Heart Association 11
PERGENE Risk Model Oemrawsingh et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at NHLI - Royal Brompton on April 4, 2016http://jaha.ahajournals.org/Downloaded from 
Maat, Maarten L. Simoons, Jasper J. Brugts, Eric Boersma and the PERGENE investigators
Willem J. Remme, Michel E. Bertrand, Kim M. Fox, Roberto Ferrari, A.H. Jan Danser, Moniek de 
Rohit M. Oemrawsingh, K. Martijn Akkerhuis, Laura C. Van Vark, W. Ken Redekop, Goran Rudez,
GENEtic (PERGENE) Risk Model
Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril 
Inhibitor Therapy in Stable Coronary−Converting Enzyme (ACE)−Individualized Angiotensin
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.115.002688
2016;5:e002688; originally published March 28, 2016;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/5/3/e002688
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 at NHLI - Royal Brompton on April 4, 2016http://jaha.ahajournals.org/Downloaded from 
